Pharvaris says Lancet study met all endpoints
Pharvaris said its phase 3 RAPIDe-3 study of deucrictibant IR in hereditary angioedema met its primary endpoint and all 11 secondary endpoints. The company also said the drug was under FDA and EMA review.
Story updates
10:37:01 PM UTC
SquawkNews
Pharvaris said RAPIDe-3 met its primary and all 11 secondary endpoints for oral deucrictibant IR in HAE attacks, with rapid symptom control and no safety signals. An NDA is under FDA review with a PDUFA target date of Apr. 23, 2027.Material DetailsContext by AI AnalystThis is late-stage confirmatio…